<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897546</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000489213</org_study_id>
    <secondary_id>ECOG-E1L06T1</secondary_id>
    <nct_id>NCT00897546</nct_id>
  </id_info>
  <brief_title>Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma</brief_title>
  <official_title>Multiplex Analysis of Serum Biomarkers for Prediction Interferon Therapy Response in Melanoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECOG-ACRIN Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the
      laboratory may help doctors learn more about changes that may occur in DNA and identify
      biomarkers related to cancer, and may help doctors learn how well patients will respond to
      treatment.

      PURPOSE: This laboratory study is looking at biomarkers to predict the response to interferon
      therapy in patients with melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Generate a comprehensive multiplexed array of melanoma-associated serological markers
           and validate it using serum samples from patients with melanoma and healthy control
           participants.

        -  Determine changes in the profile of serological markers induced by interferon-alfa 2b
           (IFN-α2b) therapy.

        -  Define panels of serological markers with prognostic and predictive power for IFN-α2b
           therapy responses in patients with melanoma.

      OUTLINE: This is a multicenter study.

      Serum samples are used for multiplex analyses. Biomarkers to be assessed include cytokines,
      chemokines, growth factors, angiogenic and antiangiogenic molecules, matrix metalloproteases
      (MMPs), tissue inhibitors of MMPs (TIMPs), melanoma-associated antigens, basic fibroblast
      growth factor, insulin-like growth factor I and II, thrombospondin, endostatin, angiostatin,
      vasostatin, and vascular endothelial growth factor inhibitor.

      PROJECTED ACCRUAL: A total of 1,716 samples will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2007</start_date>
  <completion_date type="Actual">July 1, 2008</completion_date>
  <primary_completion_date type="Actual">July 1, 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Generation of a comprehensive multiplexed array of melanoma-associated serological markers</measure>
    <time_frame>1 month</time_frame>
    <description>Generation of a comprehensive multiplexed array of melanoma-associated serological markers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the profile of serological markers induced by interferon-alfa 2b therapy</measure>
    <time_frame>1 month</time_frame>
    <description>Changes in the profile of serological markers induced by interferon-alfa 2b therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panels of serological markers with prognostic and predictive power for interferon-alfa 2b response</measure>
    <time_frame>1 month</time_frame>
    <description>Panels of serological markers with prognostic and predictive power for interferon-alfa 2b response</description>
  </secondary_outcome>
  <enrollment type="Actual">1716</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Samples submitted for research from patients participating in E1690 and E1694
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of melanoma OR healthy volunteer (control)

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elieser Gorelik, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <results_reference>
    <citation>Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007 Apr 15;13(8):2422-8.</citation>
    <PMID>17438101</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>stage IA melanoma</keyword>
  <keyword>stage IB melanoma</keyword>
  <keyword>stage IIA melanoma</keyword>
  <keyword>stage IIB melanoma</keyword>
  <keyword>stage IIC melanoma</keyword>
  <keyword>stage IIIA melanoma</keyword>
  <keyword>stage IIIB melanoma</keyword>
  <keyword>stage IIIC melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

